Elanco Animal Health Incorporat

Valuation Analysis

About the Company

Elanco Animal Health Incorporat en bref

Elanco Animal Health Incorporat (ELAN) is currently trading at 21,12 € with a market capitalization of 10,5 Md €. The 52-week range spans from 11,47 € to 24,17 €; the current price is 12.6% below the yearly high. Year-over-year revenue growth stands at +14.9%.

💰 Dividende

Elanco Animal Health Incorporat currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.

📊 Avis des analystes

14 analystes évaluent Elanco Animal Health Incorporat (ELAN) au consensus : Achat Fort. L'objectif de cours moyen est de 25,97 €, soit un potentiel de +22.93% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 20,05 € à 27,90 €.

Elanco Animal Health Incorporat : la thèse d'investissement en détail

Elanco Animal Health Incorporat (ELAN) operates in the Healthcare — specifically Drug Manufacturers - Specialty & Generic — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

Le scénario haussier

Revenue is growing at a healthy 14.9% pace year-over-year, suggesting the business model continues to find new customers and pricing power. Wall Street consensus sits at Strong Buy with an average price target implying roughly 22.93% upside from current levels — analyst sentiment is firmly constructive.

Le scénario baissier

Net margins remain negative, meaning every euro of revenue is still producing losses — the path to profitability is the central question for shareholders. Short interest sits at 10.55% of float — a meaningful contingent of professionals is positioned for the share to fall, which deserves attention even if their thesis may turn out to be wrong.

Valorisation en contexte

At a PEG of 4.04, investors are paying more than three times the growth rate for each unit of earnings — that pricing assumes growth not only continues but accelerates from here.

À surveiller

• The analyst consensus price target implies 22.93% upside — if the next two quarters confirm the underlying thesis, target hikes typically follow.

Thèse d'investissement : forces et faiblesses

Aperçu technique

Price trades above both the 50- and 200-day moving averages, with 50d above 200d — a classic bullish setup (golden-cross alignment).

Profil de risque

The data points to above-average price swings, elevated short interest (10.55%).

Trading Data

Related Stocks in the Same Sector

Where can I buy Elanco Animal Health Incorporat?

Compare top-rated brokers — low fees, trusted providers, fully regulated.